Topical tacrolimus in atopic dermatitis: Effects of ... - Helda - Helsinki.fi
Topical tacrolimus in atopic dermatitis: Effects of ... - Helda - Helsinki.fi
Topical tacrolimus in atopic dermatitis: Effects of ... - Helda - Helsinki.fi
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Quanjer PH, Tammel<strong>in</strong>g GJ, Cotes JE, Pedersen OF, Pesl<strong>in</strong> R, Yernault J-C. Lung volumes and<br />
forced expiratory flows. Eur Resp J 6(suppl):5-40, 1993<br />
Rajka G, Langeland T. Grad<strong>in</strong>g <strong>of</strong> the severity <strong>of</strong> <strong>atopic</strong> <strong>dermatitis</strong>. Acta Derm Venereol.<br />
144(suppl):13-4, 1989<br />
Rasmussen LH, Jensen LT, Avnstorp C, et al. Collagen types I and III propeptides as markers <strong>of</strong><br />
heal<strong>in</strong>g <strong>in</strong> chronic leg ulcers. A non<strong>in</strong>vasive method for the determ<strong>in</strong>ation <strong>of</strong><br />
procollagen propeptides <strong>in</strong> wound fluid – <strong>in</strong>fluence <strong>of</strong> growth hormone. Ann <strong>of</strong> Surg<br />
216:684-91, 1992<br />
Reed C. The natural history <strong>of</strong> asthma. J Allergy Cl<strong>in</strong> Immunol 118:543-8, 2006<br />
Reitamo S, Harper J, Bos JD, Cambazard F, Bruijnzeel-Koomen C, Valk P, et al. 0.03%<br />
<strong>tacrolimus</strong> o<strong>in</strong>tment applied once or twice daily is more ef<strong>fi</strong>cacious than 1%<br />
hydrocortisone acetate <strong>in</strong> children with moderate-to-severe <strong>atopic</strong> <strong>dermatitis</strong>: results <strong>of</strong><br />
a randomized double-bl<strong>in</strong>d controlled trial. Br J Dermatol 150:554-62, 2004<br />
Reitamo S, Ortonne JP, Sand C, Cambazard F, Bieber T, Folster-Holst R, Vena G, Bos JD,<br />
Fabbri P, Groenhoej Larsen C, European Tacrolimus O<strong>in</strong>tment Study Group. A<br />
multicentre, randomized, double-bl<strong>in</strong>d, controlled study <strong>of</strong> long-term treatment with<br />
0.1% <strong>tacrolimus</strong> o<strong>in</strong>tment <strong>in</strong> adults with moderate-to-severe <strong>atopic</strong> <strong>dermatitis</strong>. Br J<br />
Dermatol 152:1282-9, 2005<br />
Reitamo S, Remitz A, Kyllönen H, Saarikko J. <strong>Topical</strong> noncorticosteroid immunomodulation <strong>in</strong><br />
the treatment <strong>of</strong> <strong>atopic</strong> <strong>dermatitis</strong>. Am J Cl<strong>in</strong> Dermatol 3:381-8, 2002<br />
Reitamo S, Rust<strong>in</strong> M, Ruzicka T, Cambazard F, Kalimo K, Friedmann PS, et al. Ef<strong>fi</strong>cacy and<br />
safety <strong>of</strong> <strong>tacrolimus</strong> o<strong>in</strong>tment compared with that <strong>of</strong> hydrocortisone butyrate o<strong>in</strong>tment<br />
<strong>in</strong> adult patients with <strong>atopic</strong> <strong>dermatitis</strong>. J Allergy Cl<strong>in</strong> Immunol 109:547-55, 2002<br />
Reitamo S, Van Leent EJM, Ho V, Harper J, Ruzicka T, Kalimo K, et al. Ef<strong>fi</strong>cacy and safety <strong>of</strong><br />
<strong>tacrolimus</strong> o<strong>in</strong>tment compared with that <strong>of</strong> hydrocortisone acetate o<strong>in</strong>tment <strong>in</strong> children<br />
with <strong>atopic</strong> <strong>dermatitis</strong>. J Allergy Cl<strong>in</strong> Immunol 109: 539-46, 2002<br />
Reitamo S, Wollenberg A, Schöpf E, et al. Safety and ef<strong>fi</strong>cacy <strong>of</strong> 1 year <strong>of</strong> <strong>tacrolimus</strong> o<strong>in</strong>tment<br />
monotherapy <strong>in</strong> adults with <strong>atopic</strong> <strong>dermatitis</strong>. The European Tacrolimus O<strong>in</strong>tment<br />
Study Group. Arch Dermatol 136:999-1006, 2000<br />
Reitamo S, Rissanen J, Remitz A, Granlund H, Erkko P, Elg P, Autio P, Lauerma AI.<br />
Tacrolimus o<strong>in</strong>tment does not affect collagen synthesis: results <strong>of</strong> a s<strong>in</strong>gle-center<br />
randomized trial. J Invest Dermatol 111:396-8, 1998<br />
Remitz A, Harper J, Rust<strong>in</strong> M, Goldschmidt WF, Palatsi R, van der Valk PG, Sharpe G, Smith<br />
CH, Dobozy A, Turjanmaa K. European Tacrolimus O<strong>in</strong>tment Study Group. Longterm<br />
safety and ef<strong>fi</strong>cacy <strong>of</strong> <strong>tacrolimus</strong> o<strong>in</strong>tment for the treatment <strong>of</strong> <strong>atopic</strong> <strong>dermatitis</strong><br />
<strong>in</strong> children. Acta Derm Venereol 87:54-61, 2007<br />
Remitz A, Reitamo S, Erkko P, Granlund H, Lauerma AI. Tacrolimus o<strong>in</strong>tment improves<br />
psoriasis <strong>in</strong> a microplaque assay. Br J Dermatol 141:103-7, 1999<br />
Reynolds NJ, Frankl<strong>in</strong> V, Gray JC, Diffey BL, Farr PM. Narrow-band ultraviolet B and broadband<br />
ultraviolet A phototherapy <strong>in</strong> adult <strong>atopic</strong> eczema: a randomized controlled trial.<br />
Lancet 357:2012-6, 2001<br />
Riffo-Vasquez Y, Sp<strong>in</strong>a D, Thomas M, Gilbey T, Kemeny DM, Page CP. The role <strong>of</strong> CD23 on<br />
allergen-<strong>in</strong>duced IgE levels, pulmonary eos<strong>in</strong>ophilia and bronchial hyperresponsiveness<br />
<strong>in</strong> mice. Cl<strong>in</strong> Exp Allergy 30:728-38, 2000<br />
Rikkers SM, Holland GN, Drayton GE, et al. <strong>Topical</strong> Tacrolimus Treatment <strong>of</strong> Atopic Eyelid<br />
Disease. Am J Ophthalmol 135:297-302, 2003<br />
76
Change language